DK1468014T3 - Sammensætninger og fremgangsmåder til WT1-specifik immunterapi - Google Patents

Sammensætninger og fremgangsmåder til WT1-specifik immunterapi

Info

Publication number: DK1468014T3
Authority: DK; Denmark
Prior art keywords: compositions; polypeptide; methods; specific immunotherapy; presenting
Prior art date: 2001-10-30

Application number

DK02797061T

Other languages

English (en)

Inventor

Nomalie Jaya

Alexander Gaiger

Patricia D Mcneill

Darrick Carter

Original Assignee

Corixa Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-30

Filing date

2002-10-30

Publication date

2009-08-10

2001-10-30 Priority claimed from US10/002,603 external-priority patent/US7901693B2/en

2002-04-16 Priority claimed from US10/125,635 external-priority patent/US20030039635A1/en

2002-07-12 Priority claimed from US10/195,835 external-priority patent/US7655249B2/en

2002-10-30 Application filed by Corixa Corp filed Critical Corixa Corp

2009-08-10 Application granted granted Critical

2009-08-10 Publication of DK1468014T3 publication Critical patent/DK1468014T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

DK02797061T 2001-10-30 2002-10-30 Sammensætninger og fremgangsmåder til WT1-specifik immunterapi DK1468014T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US10/002,603 US7901693B2 (en)	1998-09-30	2001-10-30	Compositions and methods for WT1 specific immunotherapy
US10/125,635 US20030039635A1 (en)	1998-09-30	2002-04-16	Compositions and methods for WT1 specific immunotherapy
US10/195,835 US7655249B2 (en)	1998-09-30	2002-07-12	Compositions and methods for WT1 specific immunotherapy
US10/244,830 US20030235557A1 (en)	1998-09-30	2002-09-16	Compositions and methods for WT1 specific immunotherapy
PCT/US2002/035194 WO2003037060A2 (en)	2001-10-30	2002-10-30	Compositions and methods for wt1 specific immunotherapy

Publications (1)

Publication Number	Publication Date
DK1468014T3 true DK1468014T3 (da)	2009-08-10

Family

ID=27485189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02797061T DK1468014T3 (da)	2001-10-30	2002-10-30	Sammensætninger og fremgangsmåder til WT1-specifik immunterapi

Country Status (14)

Country	Link
US (1)	US20030235557A1 (da)
EP (2)	EP2172476A3 (da)
JP (1)	JP4391232B2 (da)
KR (1)	KR100970854B1 (da)
CN (1)	CN100471868C (da)
AT (1)	ATE429442T1 (da)
AU (1)	AU2002361584B2 (da)
CA (1)	CA2465303C (da)
CY (1)	CY1111002T1 (da)
DE (1)	DE60232102D1 (da)
DK (1)	DK1468014T3 (da)
ES (1)	ES2326311T3 (da)
NZ (2)	NZ560858A (da)
WO (1)	WO2003037060A2 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE420112T1 (de)	1998-07-31	2009-01-15	Int Inst Cancer Immunology Inc	Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
US7901693B2 (en)	1998-09-30	2011-03-08	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en)	1998-09-30	2008-02-12	Corixa Corporation	Compositions and method for WT1 specific immunotherapy
US7655249B2 (en)	1998-09-30	2010-02-02	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
ATE383375T1 (de) *	2001-03-22	2008-01-15	Int Inst Cancer Immunology Inc	Wti-modifiziertes peptid
US7553494B2 (en)	2001-08-24	2009-06-30	Corixa Corporation	WT1 fusion proteins
ATE538809T1 (de)	2003-06-27	2012-01-15	Int Inst Cancer Immunology Inc	Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
US8911991B2 (en) *	2003-09-05	2014-12-16	Sanofi Pasteur Limited	Multi-antigen vectors of melanoma
PL2071028T3 (pl)	2003-11-05	2012-06-29	Int Inst Cancer Immunology Inc	Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
WO2005053618A2 (en) *	2003-12-01	2005-06-16	Sloan-Kettering Institute For Cancer Research	Synthetic hla binding peptide analogues and uses thereof
EP1720565A1 (en) *	2004-03-04	2006-11-15	Corixa Corporation	Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
PT1731605E (pt)	2004-03-31	2010-04-14	Int Inst Cancer Immunology Inc	Péptidos antigénicos de cancro derivados de wt1
EP1657250A1 (en) *	2004-11-11	2006-05-17	Charité - Universitätsmedizin Berlin	HLA-A *01-binding T-cell epitope of WT1
CA2626238C (en)	2005-10-17	2015-10-06	Sloan Kettering Institute For Cancer Research	Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP2518149B1 (en)	2006-02-22	2015-12-16	International Institute of Cancer Immunology, Inc.	HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
EP3834836A1 (en)	2006-04-10	2021-06-16	Memorial Sloan Kettering Cancer Center	Immunogenic wt-1 peptides and uses thereof
CN100460013C (zh) *	2006-09-05	2009-02-11	重庆康卫生物科技有限公司	口服重组幽门螺杆菌疫苗及其制备方法
AU2012227350C1 (en) *	2006-12-28	2015-11-12	International Institute Of Cancer Immunology, Inc.	HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
NZ592509A (en) *	2006-12-28	2012-11-30	Int Inst Cancer Immunology Inc	HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
AU2008220031B2 (en) *	2007-02-27	2013-06-13	International Institute Of Cancer Immunology, Inc.	Method for activation of helper T cell and composition for use in the method
WO2008108257A1 (ja)	2007-03-05	2008-09-12	International Institute Of Cancer Immunology, Inc.	癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
TW200911304A (en) *	2007-05-24	2009-03-16	Glaxosmithkline Biolog Sa	Lyophillised antigen composition
CN101835792B (zh) *	2007-08-20	2015-04-15	肿瘤疗法科学股份有限公司	Foxm1肽和包含foxm1肽的药剂
US20100255020A1 (en) *	2007-11-20	2010-10-07	Nec Corporation	Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them
TWI469791B (zh)	2009-02-18	2015-01-21	Oncotherapy Science Inc	Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
AR076349A1 (es) *	2009-04-23	2011-06-01	Int Inst Cancer Immunology Inc	Peptido auxiliar del antigeno del cancer
DK2483417T3 (da) *	2009-09-29	2017-05-15	Univ Pennsylvania	Fremgangsmåder til diagnosticering og behandling af encephalitis eller epilepsi
BR112013008230A2 (pt)	2010-10-05	2016-06-14	Int Inst Cancer Immunology Inc	método para ativar célula t auxiliar
CN102161998B (zh) *	2011-01-14	2013-01-09	中国人民解放军军事医学科学院附属医院	基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途
WO2013002086A1 (ja)	2011-06-28	2013-01-03	株式会社癌免疫研究所	ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
CN103797369B (zh) *	2011-09-14	2017-09-19	株式会社癌免疫研究所	抗wt1抗体的测定方法
US20150104413A1 (en)	2012-01-13	2015-04-16	Memorial Sloan Kettering Cancer Center	Immunogenic wt-1 peptides and methods of use thereof
PL2931304T3 (pl) *	2012-12-13	2021-11-08	The Trustees Of The University Of Pennsylvania	Szczepionka wt1
CN110195040A (zh)	2012-12-17	2019-09-03	大塚制药株式会社	辅助性t细胞的活化方法
RS61173B1 (sr) *	2013-01-15	2021-01-29	Memorial Sloan Kettering Cancer Center	Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
US10815273B2 (en)	2013-01-15	2020-10-27	Memorial Sloan Kettering Cancer Center	Immunogenic WT-1 peptides and methods of use thereof
CN103961702B (zh)	2013-02-05	2019-04-09	日东电工株式会社	粘膜给予用wt1肽癌症疫苗组合物
WO2014185387A1 (ja) *	2013-05-13	2014-11-20	株式会社癌免疫研究所	免疫療法の臨床効果の予測法
AU2014290288B2 (en) *	2013-07-15	2018-03-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-human papillomavirus 16 E6 T cell receptors
US10253075B2 (en)	2014-02-26	2019-04-09	tella, Inc.	WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
CN107073090A (zh)	2014-04-30	2017-08-18	哈佛学院董事会	结合的疫苗装置和杀死癌细胞的方法
JP6991969B2 (ja)	2015-11-20	2022-03-03	メモリアルスローンケタリングキャンサーセンター	癌を治療するための方法及び組成物
CN105254760B (zh) *	2015-11-21	2018-08-17	福州迈新生物技术开发有限公司	一株分泌抗wt1蛋白的单克隆抗体及其应用
EP3411475A4 (en)	2016-02-06	2019-09-11	President and Fellows of Harvard College	REGENERATION OF THE HEMATOPOIETIC NICHE TO RECONSTITUTE IMMUNITY
CN115305229A (zh)	2016-07-13	2022-11-08	哈佛学院院长等	抗原呈递细胞模拟支架及其制备和使用方法
CA3035075A1 (en) *	2016-09-23	2018-03-29	Fred Hutchinson Cancer Research Center	Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
EP3549957A4 (en)	2016-11-30	2020-08-05	Sumitomo Dainippon Pharma Co., Ltd.	WT1-HELPER PEPTIDE AND COMBINATION OF THE SAYING PEPTIDE AND A CANCER ANTIGEN PEPTIDE CONJUGATE
EP3604325A4 (en)	2017-03-30	2021-01-13	Sumitomo Dainippon Pharma Co., Ltd.	WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
WO2018227205A1 (en) *	2017-06-09	2018-12-13	President And Fellows Of Harvard College	Compositions for inducing an immune response
WO2020067453A1 (ja)	2018-09-28	2020-04-02	大日本住友製薬株式会社	注射用組成物
CN115867303A (zh)	2020-05-12	2023-03-28	住友制药株式会社	用于治疗癌症的药物组合物
TW202315645A (zh)	2021-08-12	2023-04-16	日商癌免疫研究所股份有限公司	用以處置或預防癌症之醫藥組合物及方法
CN113730562B (zh) *	2021-09-10	2024-06-04	中国人民解放军陆军军医大学	以壳聚糖修饰plga的wt1多肽纳米粒疫苗及其制备方法和应用

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US18795A (en) *		1857-12-01		James s
US4489710A (en)	1981-06-23	1984-12-25	Xoma Corporation	Composition and method for transplantation therapy
US4429008B1 (en)	1981-12-10	1995-05-16	Univ California	Thiol reactive liposomes
US4769330A (en)	1981-12-24	1988-09-06	Health Research, Incorporated	Modified vaccinia virus and methods for making and using the same
US4603112A (en)	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
US4671958A (en)	1982-03-09	1987-06-09	Cytogen Corporation	Antibody conjugates for the delivery of compounds to target sites
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
JPS59116229A (ja)	1982-12-24	1984-07-05	Teijin Ltd	細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4673562A (en)	1983-08-19	1987-06-16	The Children's Medical Center Corporation	Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4873088A (en)	1983-09-06	1989-10-10	Liposome Technology, Inc.	Liposome drug delivery method and composition
US4625014A (en)	1984-07-10	1986-11-25	Dana-Farber Cancer Institute, Inc.	Cell-delivery agent
US4542225A (en)	1984-08-29	1985-09-17	Dana-Farber Cancer Institute, Inc.	Acid-cleavable compound
US4708930A (en)	1984-11-09	1987-11-24	Coulter Corporation	Monoclonal antibody to a human carcinoma tumor associated antigen
US4918164A (en)	1987-09-10	1990-04-17	Oncogen	Tumor immunotherapy using anti-idiotypic antibodies
US4638045A (en)	1985-02-19	1987-01-20	Massachusetts Institute Of Technology	Non-peptide polyamino acid bioerodible polymers
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
GB8508845D0 (en)	1985-04-04	1985-05-09	Hoffmann La Roche	Vaccinia dna
US4777127A (en)	1985-09-30	1988-10-11	Labsystems Oy	Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US4699784A (en)	1986-02-25	1987-10-13	Center For Molecular Medicine & Immunology	Tumoricidal methotrexate-antibody conjugate
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US6024983A (en)	1986-10-24	2000-02-15	Southern Research Institute	Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en)	1986-10-24	1991-12-24	Southern Research Institute	Method of potentiating an immune response
GB8702816D0 (en)	1987-02-07	1987-03-11	Al Sumidaie A M K	Obtaining retrovirus-containing fraction
US5219740A (en)	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
US4735792A (en)	1987-04-28	1988-04-05	The United States Of America As Represented By The United States Department Of Energy	Radioiodinated maleimides and use as agents for radiolabeling antibodies
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4897268A (en)	1987-08-03	1990-01-30	Southern Research Institute	Drug delivery system and method of making the same
DE10399031I1 (de)	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
WO1989001973A2 (en)	1987-09-02	1989-03-09	Applied Biotechnology, Inc.	Recombinant pox virus for immunization against tumor-associated antigens
AU2613988A (en)	1988-01-04	1989-08-01	E.I. Du Pont De Nemours And Company	Multiple stage affinity process for isolation of specific cells from a cell mixture
US5215926A (en)	1988-06-03	1993-06-01	Cellpro, Inc.	Procedure for designing efficient affinity cell separation processes
AP129A (en)	1988-06-03	1991-04-17	Smithkline Biologicals S A	Expression of retrovirus gag protein eukaryotic cells
US5747324A (en)	1988-06-10	1998-05-05	Therion Biologics Corporation	Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en)	1988-06-10	1997-05-20	Therion Biologics, Incorporated	Self assembled, defective, non-self-propagating lentivirus particles
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
ES2084698T5 (es)	1989-05-04	2005-03-01	Southern Research Institute	Procedimiento de encapsulacion.
AU648261B2 (en)	1989-08-18	1994-04-21	Novartis Vaccines And Diagnostics, Inc.	Recombinant retroviruses delivering vector constructs to target cells
US5725871A (en)	1989-08-18	1998-03-10	Danbiosyst Uk Limited	Drug delivery compositions comprising lysophosphoglycerolipid
KR920007887B1 (ko)	1989-08-29	1992-09-18	스즈키 지도오샤 고오교오 가부시키가이샤	내연기관의 배기가스 정화장치
US5707644A (en)	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5726288A (en) *	1989-11-13	1998-03-10	Massachusetts Institute Of Technology	Localization and characterization of the Wilms' tumor gene
WO1991007509A1 (en) *	1989-11-13	1991-05-30	Massachusetts Institute Of Technology	Localization and characterization of the wilms's tumor gene
WO1991007487A1 (en)	1989-11-16	1991-05-30	Duke University	Particle-mediated transformation of animal tissue cells
FR2658432B1 (fr)	1990-02-22	1994-07-01	Medgenix Group Sa	Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5466468A (en)	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
WO1991016116A1 (en)	1990-04-23	1991-10-31	Cellpro Incorporated	Immunoselection device and method
SE466259B (sv)	1990-05-31	1992-01-20	Arne Forsgren	Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992001070A1 (en)	1990-07-09	1992-01-23	The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce	High efficiency packaging of mutant adeno-associated virus using amber suppressions
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
ATE163047T1 (de)	1990-08-15	1998-02-15	Therion Biolog Corp	Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel
MY109299A (en)	1990-08-15	1996-12-31	Virogenetics Corp	Recombinant pox virus encoding flaviviral structural proteins
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DK0553288T3 (da)	1990-10-18	1997-12-29	Cellpro Inc	Apparat og fremgangsmåde til udskillelse af partikler ved brug af en eftergivende beholder
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
ATE237694T1 (de)	1991-08-20	2003-05-15	Us Gov Health & Human Serv	Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5240856A (en)	1991-10-23	1993-08-31	Cellpro Incorporated	Apparatus for cell separation
JPH07501942A (ja) *	1991-11-29	1995-03-02	カイロン　コーポレイション	抗ガン免疫療法用ベクター構成体
US5756353A (en)	1991-12-17	1998-05-26	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de)	1992-05-18	1997-08-15	Minnesota Mining & Mfg	Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
SK279188B6 (sk)	1992-06-25	1998-07-08	Smithkline Beecham Biologicals S.A.	Vakcínová kompozícia spôsob jej prípravy a použiti
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US5928647A (en)	1993-01-11	1999-07-27	Dana-Farber Cancer Institute	Inducing cytotoxic T lymphocyte responses
US5359681A (en)	1993-01-11	1994-10-25	University Of Washington	Fiber optic sensor and methods and apparatus relating thereto
US5633234A (en)	1993-01-22	1997-05-27	The Johns Hopkins University	Lysosomal targeting of immunogens
US5654186A (en)	1993-02-26	1997-08-05	The Picower Institute For Medical Research	Blood-borne mesenchymal cells
FR2702160B1 (fr)	1993-03-02	1995-06-02	Biovecteurs As	Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr)	1993-04-21	1995-07-21	Pasteur Institut	Vecteur particulaire et composition pharmaceutique le contenant.
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
CA2147991A1 (en)	1993-09-01	1995-03-09	Richard A. Glennon	Tryptamine analogs with 5-ht1d selectivity
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
DK0690732T3 (da)	1994-01-21	2003-05-19	Powderject Vaccines Inc	Gasdrevet genindførselsinstrument
US5622835A (en) *	1994-04-28	1997-04-22	The Wistar Institute Of Anatomy & Biology	WT1 monoclonal antibodies
US5656465A (en)	1994-05-04	1997-08-12	Therion Biologics Corporation	Methods of in vivo gene delivery
US5505947A (en)	1994-05-27	1996-04-09	The University Of North Carolina At Chapel Hill	Attenuating mutations in Venezuelan Equine Encephalitis virus
DK0772619T4 (da)	1994-07-15	2011-02-21	Univ Iowa Res Found	Immunmodulatoriske oligonukleotider
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
GB9502879D0 (en)	1995-02-14	1995-04-05	Oxford Biosciences Ltd	Particle delivery
US5580579A (en)	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US6001349A (en)	1995-02-22	1999-12-14	Therion Biologics Corporation	Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5830755A (en)	1995-03-27	1998-11-03	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	T-cell receptors and their use in therapeutic and diagnostic methods
IE80468B1 (en)	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5670317A (en) *	1995-05-08	1997-09-23	Sloan-Kettering Institute For Cancer Research	Diagnostic test for the desmoplastic small round cell tumor
DE69636339T2 (de) *	1995-06-01	2007-07-19	Kishimoto, Tadamitsu, Tondabayashi	Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms-tumorgen enthält
US6165460A (en)	1995-07-10	2000-12-26	Therion Biologics Corporation	Generation of immune responses to prostate-specific antigen (PSA)
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
JP2002515734A (ja)	1996-01-02	2002-05-28	カイロンコーポレイション	遺伝子改変された樹状細胞により媒介される免疫刺激
US6096313A (en) *	1996-02-09	2000-08-01	Ludwig Institute For Cancer Research	Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5856462A (en)	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
US5811407A (en)	1997-02-19	1998-09-22	The University Of North Carolina At Chapel Hill	System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6113918A (en)	1997-05-08	2000-09-05	Ribi Immunochem Research, Inc.	Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en)	1997-05-08	2001-10-16	Corixa Corporation	Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en)	1997-05-08	2002-03-12	Corixa Corporation	Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en)	1997-05-19	1999-11-30	Bioject, Inc.	Injection apparatus
GB9727262D0 (en)	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
CN100387622C (zh)	1998-02-12	2008-05-14	免疫合成物公司	策略性修饰的乙肝核心蛋白及其衍生物
EP1068339B1 (en) *	1998-04-01	2008-07-23	The Governors of the University of Alberta	Compositions and methods for protein secretion
NZ506603A (en)	1998-04-09	2002-10-25	Smithkline Beecham Biolog S	Adjuvant compositions comprising polyoxyethylene ether or polyoxyethylene ester
US7049302B1 (en)	1998-08-10	2006-05-23	Antigenics Inc.	Compositions of CPG and saponin adjuvants and uses thereof
JP4243792B2 (ja) *	1998-09-30	2009-03-25	コリクサコーポレイション	Ｗｔ１特異的免疫療法のための組成物および方法
GB9823897D0 (en) *	1998-11-02	1998-12-30	Imp College Innovations Ltd	Immunotherapeutic methods and molecules
EP1150918B1 (en)	1999-02-03	2004-09-15	Biosante Pharmaceuticals, Inc.	Method of manufacturing therapeutic calcium phosphate particles
NZ521430A (en) *	2000-02-22	2004-04-30	Corixa Corp	Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma

2002
- 2002-09-16 US US10/244,830 patent/US20030235557A1/en not_active Abandoned
- 2002-10-30 KR KR1020047006659A patent/KR100970854B1/ko not_active IP Right Cessation
- 2002-10-30 JP JP2003539419A patent/JP4391232B2/ja not_active Expired - Fee Related
- 2002-10-30 CN CNB028264924A patent/CN100471868C/zh not_active Expired - Fee Related
- 2002-10-30 DK DK02797061T patent/DK1468014T3/da active
- 2002-10-30 DE DE60232102T patent/DE60232102D1/de not_active Expired - Lifetime
- 2002-10-30 AT AT02797061T patent/ATE429442T1/de active
- 2002-10-30 NZ NZ560858A patent/NZ560858A/en not_active IP Right Cessation
- 2002-10-30 CA CA2465303A patent/CA2465303C/en not_active Expired - Fee Related
- 2002-10-30 EP EP09153790A patent/EP2172476A3/en not_active Withdrawn
- 2002-10-30 ES ES02797061T patent/ES2326311T3/es not_active Expired - Lifetime
- 2002-10-30 EP EP02797061A patent/EP1468014B1/en not_active Expired - Lifetime
- 2002-10-30 NZ NZ533220A patent/NZ533220A/en not_active IP Right Cessation
- 2002-10-30 WO PCT/US2002/035194 patent/WO2003037060A2/en active Application Filing
- 2002-10-30 AU AU2002361584A patent/AU2002361584B2/en not_active Ceased
2009
- 2009-07-22 CY CY20091100785T patent/CY1111002T1/el unknown

Also Published As

Publication number	Publication date
ATE429442T1 (de)	2009-05-15
EP1468014B1 (en)	2009-04-22
EP1468014A4 (en)	2006-05-17
DE60232102D1 (de)	2009-06-04
WO2003037060A3 (en)	2004-08-12
CA2465303C (en)	2011-09-13
WO2003037060A2 (en)	2003-05-08
AU2002361584B2 (en)	2009-07-23
JP2005518192A (ja)	2005-06-23
ES2326311T3 (es)	2009-10-07
KR20050042226A (ko)	2005-05-06
JP4391232B2 (ja)	2009-12-24
US20030235557A1 (en)	2003-12-25
EP2172476A2 (en)	2010-04-07
CY1111002T1 (el)	2015-06-11
CN100471868C (zh)	2009-03-25
CN1671733A (zh)	2005-09-21
EP2172476A3 (en)	2010-06-23
CA2465303A1 (en)	2003-05-08
NZ560858A (en)	2009-06-26
KR100970854B1 (ko)	2010-07-20
EP1468014A2 (en)	2004-10-20
NZ533220A (en)	2008-04-30

Publication	Publication Date	Title
DK1468014T3 (da)	2009-08-10	Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
ATE402189T1 (de)	2008-08-15	Verbindungen und methoden zur wt1-spezifischen immuntherapie
TW200509967A (en)	2005-03-16	Compositions and methods for WT1 specific immunotherapy
TW200606176A (en)	2006-02-16	Compositions and methods for wt1 specific immunotherapy
WO2001025273A3 (en)	2002-07-11	Compositions and methods for wt1 specific immunotherapy
DK1349870T3 (da)	2009-02-09	Sammensætninger til terapien og diagnosen af ovariecancer
HUP0203968A2 (hu)	2003-03-28	Készítmények és eljárások prosztatarák terápiájára és diagnózisára
EA200800268A1 (ru)	2008-06-30	КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
NZ512247A (en)	2004-01-30	Compositions and methods for therapy and diagnosis of ovarian cancer
WO2004058171A3 (en)	2006-08-03	Antibodies against gpr64 and uses thereof
DK1187632T3 (da)	2009-04-06	Behandling med anti-ErbB2-antistoffer
CY1108127T1 (el)	2014-02-12	Μεθοδοι για την προστασια αλλογενους μοσχευματος παγκρεατικων νησιδιων με χρηση διαλυτων μοριων μεταλλακτων ctla4
HUP0300590A2 (hu)	2003-07-28	Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
HUP0402656A2 (hu)	2005-03-29	Sejtterápiás eljárás tumorok kezelésére
WO2002078516A3 (en)	2004-03-18	Compositions and methods for the therapy and diagnosis of cancer
WO2001018046A3 (en)	2001-09-13	Ovarian tumor sequences and methods of use therefor
ATE431742T1 (de)	2009-06-15	Modifizierte zytokine für krebs therapie
ATE475710T1 (de)	2010-08-15	Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
MXPA05009428A (es)	2005-12-12	Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2003081250A8 (en)	2005-02-03	Novel compositions and methods in cancer associated with altered expression of prlr
DK1444261T3 (da)	2006-03-20	Immunogene ALK (anaplastisk lymfomakinase) peptider
NO20062358L (no)	2006-07-12	Jombinasjoner for behandling av proliferative sykdommer
UY27768A1 (es)	2003-11-28	2-(2,6- diclorofenil)-diarilimidazoles